Wealthcare Advisory Partners’s Cytosorbents Corp CTSO Stock Holding History

Wealthcare Advisory Partners’s Portfolio CTSO Stock Details CTSO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-62,187	Closed	-$505K	–	586
2021 Q3	$505K	Hold	62,187	–	–	0.03%	312
2021 Q2	$470K	Hold	62,187	–	–	0.03%	330
2021 Q1	$540K	Hold	62,187	–	–	0.04%	275
2020 Q4	$496K	Hold	62,187	–	–	0.04%	238
2020 Q3	$496K	Hold	62,187	–	–	0.05%	199
2020 Q2	$616K	Hold	62,187	–	–	0.08%	151
2020 Q1	$481K	Sell	62,187 -92	-0.1%	-$464	0.07%	149
2019 Q4	$240K	Hold	62,279	–	–	0.03%	267
2019 Q3	$313K	Buy	62,279 +200	+0.3%	+$1.16K	0.05%	207
2019 Q2	$410K	Hold	62,079	–	–	0.07%	161
2019 Q1	$470K	Hold	62,079	–	–	0.08%	143
2018 Q4	$502K	Hold	62,079	–	–	0.1%	118
2018 Q3	$801K	Hold	62,079	–	–	0.15%	88
2018 Q2	$708K	Hold	62,079	–	–	0.14%	91
2018 Q1	$438K	Buy	62,079 +3,180	+5%	+$24K	0.1%	115
2017 Q4	$383K	Hold	58,899	–	–	0.1%	115
2017 Q3	$365K	Buy	+58,899	New	+$300K	0.11%	103

Other funds holding CTSO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Skylands Capital Milwaukee, Wisconsin $763M AUM 26.49% 1-Year Est. Return

Avenir Corporation Alexandria, Virginia $820M AUM 2.4% 1-Year Est. Return

Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

SIG

Sargent Investment Group Bethesda, Maryland $759M AUM 28.58% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wealthcare Advisory Partners's CTSO Position: Q4 2021 in Review

Wealthcare Advisory Partners sold out of Cytosorbents Corp (CTSO) in Q4 2021, closing a stake of 62,187 shares — an estimated $505K sold.

Wealthcare Advisory Partners first reported a position in CTSO in Q3 2017 and held it in 17 quarters. The position peaked at $801K in Q3 2018. 91 funds tracked by Wall St. Rank hold CTSO as of Q4 2021.

Wealthcare Advisory Partners reported no remaining Cytosorbents Corp position as of Q4 2021 after selling out during the quarter.
Wealthcare Advisory Partners sold 62,187 Cytosorbents Corp shares in Q4 2021, an estimated $505K.
Wealthcare Advisory Partners first reported a position in Cytosorbents Corp in Q3 2017 and held it in 17 quarters.
Wealthcare Advisory Partners's Cytosorbents Corp position peaked at $801K in Q3 2018.
91 funds tracked by Wall St. Rank held Cytosorbents Corp as of Q4 2021.

Based on Wealthcare Advisory Partners's 13F filing for Q4 2021, filed 11 Feb 2022.